- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05386953
Intraoperativ normal saltvandsadministration og akut nyreskade hos patienter, der gennemgår levertransplantation
Intraoperativ normal saltvandsadministration og akut nyreskade hos patienter, der gennemgår levertransplantation: en retrospektiv kohorteundersøgelse
The investigators attempted to investigate the association of the type of crystalloid administered during liver transplantation with postoperative clinical outcomes. The investigators hypothesized that the greater amount of normal saline or half-saline administered during liver transplantation might be associated with the increased risk of acute kidney injury compared to the balanced crystalloids.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Liver transplantation requires a long operation time and is often associated with a significant amount of surgical bleeding. It is common for the anesthesiologist to infuse large amounts of fluid or blood products due to bleeding, hemodynamic instability, or ascites drainage. Therefore, in the anesthesia for liver transplantation, optimal management of fluid administration is necessary and the choice of the type of crystalloid may affect the prognosis or the incidence of postoperative complications of patients.
The investigators attempted to investigate the association of the type of crystalloid administered during liver transplantation with postoperative clinical outcomes. The investigators hypothesized that the greater amount of normal saline or half-saline administered during liver transplantation might be associated with the increased risk of acute kidney injury compared to the balanced crystalloids.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
-
Seoul, Sydkorea, 03080
- Seoul National University Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients received liver transplantation surgery in a single tertiary care university hospital
Beskrivelse
Inclusion Criteria:
- Consecutive patients who underwent living or deceased donor liver transplantation at our tertiary care university hospital between 2004 and 2018
Exclusion Criteria:
- patients with baseline renal dysfunction of hepatorenal syndrome or chronic kidney disease
- missing preoperative serum creatinine value
- missing other baseline or outcome variables
- patients who received retransplantation
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: RETROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Balanced group
Patients who received balanced crystalloids of lactated Ringer's solution or plasma solution during liver transplantation surgery |
Patients received balanced crystalloids such as lactated Ringer's solution or Plasma solution as a maintenance crystalloid during liver transplantation surgery.
Andre navne:
|
|
Saline group
Patients who received only normal saline during liver transplantation surgery |
Patients received normal saline as a maintenance crystalloid during liver transplantation surgery. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Acute kidney injury
Tidsramme: the first 7 postoperative days
|
The investigators defined acute kidney injury by the KDIGO (Kidney Disease Improving Global Outcomes) criteria, which was determined according to the greatest change in serum creatinine level during the postoperative seven days (Stage 1: more than 1.5-fold; stage 2: more than 2-fold; stage 3: more than 3-fold increase of baseline or increase in SCr to ≥ 4.0 mg/dL or the initiation of renal replacement therapy). The most recent SCr level measured before surgery was collected as a baseline value. |
the first 7 postoperative days
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of postoperative hemodialysis
Tidsramme: the first month after admission
|
the incidence of new-onset postoperative hemodialysis during hospitalization |
the first month after admission
|
|
Early allograft dysfunction
Tidsramme: the first 7 postoperative days
|
One or more of the following are present within the first 7 postoperative days: total bilirubin ≥ 10 mg/dL, PT (prothrombin time):INR (international normalized ratio)≥ 1.6, or AST (aspartate aminotransferase)/ALT (alanine aminotransferase) > 2000 IU/L |
the first 7 postoperative days
|
|
In-hospital mortality
Tidsramme: the first month after admission
|
all-cause mortality during hospitalization |
the first month after admission
|
|
One-year mortality
Tidsramme: one year after transplantation
|
all-cause mortality during one year after transplantation |
one year after transplantation
|
|
Length of intensive care unit stay
Tidsramme: the first month after admission
|
Length of intensive care unit stay after transplantation |
the first month after admission
|
|
Length of hospital stay
Tidsramme: the first month after admission
|
Length of hospital stay after transplantation |
the first month after admission
|
Samarbejdspartnere og efterforskere
Efterforskere
- Studiestol: Won Ho Kim, MD, PhD, Department of Anaesthesiology and Pain Medicine, Seoul National University Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Sygdomme i fordøjelsessystemet
- Leversygdomme
- Leversvigt
- Leverinsufficiens
- Fibrose
- Patologiske tilstande, tegn og symptomer
- Levercirrhose
- Slutstadie leversygdom
- Farmaceutiske præparater
- Krystalloidopløsninger
- Isotoniske løsninger
- Løsninger
- Salinopløsning
- Ringer's laktat
- stable plasma protein solution
Andre undersøgelses-id-numre
- H-2108-173-1248
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .